

Jrgen Vestbo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/648643/jorgen-vestbo-publications-by-citations.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

445
papers

43,415
citations

97
h-index

200
g-index

502
ext. papers

51,117
ext. citations

9.6
avg, IF

7.28
L-index

#	Paper	IF	Citations
445	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 347-65	10.2	3654
444	Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2007 , 356, 775-89	59.2	2457
443	Susceptibility to exacerbation in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1128-38	59.2	1840
442	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 557-582	10.2	1682
441	A 15-year follow-up study of ventilatory function in adults with asthma. <i>New England Journal of Medicine</i> , 1998 , 339, 1194-200	59.2	969
440	Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2003 , 361, 449-56	40	961
439	Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , 2010 , 11, 122	7.3	752
438	Prognostic value of nutritional status in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 160, 1856-61	10.2	726
437	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	722
436	Chronic obstructive pulmonary disease phenotypes: the future of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 598-604	10.2	678
435	Changes in forced expiratory volume in 1 second over time in COPD. <i>New England Journal of Medicine</i> , 2011 , 365, 1184-92	59.2	654
434	Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 1999 , 353, 1819-23	40	632
433	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2015 , 373, 111-22	59.2	595
432	Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 332-8	10.2	566
431	Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. <i>New England Journal of Medicine</i> , 2016 , 374, 2222-34	59.2	537
430	Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. <i>PLoS ONE</i> , 2012 , 7, e37483	3.7	521
429	Treatable traits: toward precision medicine of chronic airway diseases. <i>European Respiratory Journal</i> , 2016 , 47, 410-9	13.6	487

428	Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). <i>European Respiratory Journal</i> , 2008 , 31, 869-73	13.6	486
427	Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. <i>European Respiratory Journal</i> , 2002 , 20, 799-805	13.6	410
426	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	398
425	C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 250-5	10.2	391
424	Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 79-83	10.2	386
423	Developing COPD: a 25 year follow up study of the general population. <i>Thorax</i> , 2006 , 61, 935-9	7.3	377
422	Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. <i>European Respiratory Journal</i> , 2009 , 34, 641-7	13.6	314
421	Adherence to inhaled therapy, mortality and hospital admission in COPD. <i>Thorax</i> , 2009 , 64, 939-43	7.3	309
420	Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 975-81	10.2	305
419	Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 1076-1084	40	300
418	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , 2015 , 46, 1308-21	13.6	292
417	Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1065-72	10.2	288
416	Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 523-5	10.2	273
415	Chronic obstructive pulmonary disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15076	51.1	270
414	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1817-26	40	263
413	Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 965-74	10.2	260
412	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	256
411	Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β_2 -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2016 , 388, 963-73	40	256

410	Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 2353-61	27.4	253
409	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 210-23	35.1	249
408	Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample: Findings from the Copenhagen City Heart Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 79-83	10.2	248
407	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 128-149	0.7	247
406	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2013 , 107, 1376-84	4.6	243
405	Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017 , 389, 1919-1929	4.0	235
404	Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 500-5	10.2	235
403	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , 2009 , 10, 59	7.3	234
402	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , 2017 , 22, 575-601	3.6	228
401	Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. <i>European Respiratory Journal</i> , 2002 , 20, 819-25	13.6	218
400	Epidemiology of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2001 , 17, 982-94	13.6	216
399	Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 382-6	10.2	206
398	Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. <i>Chest</i> , 2015 , 147, 999-1007	5.3	204
397	Prevalence and progression of osteoporosis in patients with COPD: results from the TOWARDS a Revolution in COPD Health study. <i>Chest</i> , 2009 , 136, 1456-1465	5.3	202
396	Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 604-11	10.2	202
395	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. <i>Nature Genetics</i> , 2017 , 49, 426-432	36.3	201
394	Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 166, 329-32	10.2	189
393	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 129-36	35.1	183

392	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. <i>Human Molecular Genetics</i> , 2012 , 21, 947-57	5.6	181
391	Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 1008-11	10.2	179
390	COPD-related morbidity and mortality after smoking cessation: status of the evidence. <i>European Respiratory Journal</i> , 2008 , 32, 844-53	13.6	178
389	Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. <i>European Respiratory Journal</i> , 2002 , 20, 539-44	13.6	178
388	The natural history of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2006 , 27, 627-43	13.6	174
387	Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005 , 60, 992-7	7.3	170
386	Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. <i>Journal of the American Medical Directors Association</i> , 2012 , 13, 291-7	5.9	167
385	Chronic mucus hypersecretion in COPD and death from pulmonary infection. <i>European Respiratory Journal</i> , 1995 , 8, 1333-8	13.6	165
384	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1797-1807	11.5	163
383	Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 982-8	10.2	159
382	COPD: the dangerous underestimate of 15%. <i>Lancet, The</i> , 2006 , 367, 1216-9	40	159
381	Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. <i>European Respiratory Journal</i> , 1999 , 13, 1109-14	13.6	155
380	Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. <i>European Respiratory Journal</i> , 2012 , 39, 38-45	13.6	150
379	Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2010 , 104, 849-57	4.6	148
378	Cardiovascular events in patients with COPD: TORCH study results. <i>Thorax</i> , 2010 , 65, 719-25	7.3	142
377	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013 , 42, 636-46	13.6	139
376	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, e4-e27	10.2	137
375	Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. <i>New England Journal of Medicine</i> , 2016 , 375, 1253-60	59.2	136

374	Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. <i>American Journal of Epidemiology</i> , 2002 , 156, 994-1001	3.8	125
373	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012 , 67, 701-8	7.3	122
372	Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 317-22	10.2	122
371	Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. <i>Thorax</i> , 2002 , 57, 967-72	7.3	120
370	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. <i>Nature Genetics</i> , 2019 , 51, 494-505	36.3	119
369	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , 2014 , 69, 718-23	7.3	118
368	Short telomere length, lung function and chronic obstructive pulmonary disease in 46,396 individuals. <i>Thorax</i> , 2013 , 68, 429-35	7.3	118
367	Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 1022-30	10.2	117
366	The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?. <i>Clinical Respiratory Journal</i> , 2012 , 6, 208-14	1.7	116
365	Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. <i>Respiratory Medicine</i> , 2004 , 98, 1207-13	4.6	115
364	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014 , 44, 304-23	13.6	112
363	Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. <i>Annals of Internal Medicine</i> , 2002 , 136, 270-9	8	112
362	Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. <i>Thorax</i> , 2008 , 63, 1064-9	7.3	111
361	Mortality in women and men in relation to smoking. <i>International Journal of Epidemiology</i> , 1998 , 27, 27-32, 8		111
360	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015 , 45, 879-905	13.6	107
359	Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. <i>New England Journal of Medicine</i> , 2011 , 365, 2541-2	59.2	105
358	MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 1033-9	10.2	104
357	Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. <i>European Respiratory Journal</i> , 2011 , 37, 508-15	13.6	103

356	Potential misclassification of causes of death from COPD. <i>European Respiratory Journal</i> , 2006 , 28, 781-5	13.6	103
355	Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014 , 69, 666-72	7.3	102
354	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	102
353	Changes in physical activity and all-cause mortality in COPD. <i>European Respiratory Journal</i> , 2014 , 44, 1199-209	13.6	100
352	A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. <i>Chest</i> , 2007 , 131, 682-689	5.3	99
351	A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. <i>Nicotine and Tobacco Research</i> , 2004 , 6, 55-61	4.9	99
350	Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 27-34	4.7	98
349	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 51-57	10.2	97
348	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 2037-2047.e10	11.5	95
347	Recommendations for epidemiological studies on COPD. <i>European Respiratory Journal</i> , 2011 , 38, 1261-71	13.6	95
346	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1540-1551	10.2	94
345	Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 303-12	4.7	93
344	CD4-regulatory cells in COPD patients. <i>Chest</i> , 2007 , 132, 156-63	5.3	90
343	The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 2170-2184	9.3	90
342	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	89
341	Inhaled corticosteroids and decline of lung function in community residents with asthma. <i>Thorax</i> , 2006 , 61, 100-4	7.3	89
340	Possible gene dosage effect of glutathione-S-transferases on atopic asthma: using real-time PCR for quantification of GSTM1 and GSTT1 gene copy numbers. <i>Human Mutation</i> , 2004 , 24, 208-14	4.7	89
339	Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 1238-47	10.2	88

338	Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. <i>Treatments in Respiratory Medicine</i> , 2003 , 2, 67-74		86
337	Chronic obstructive pulmonary disease in patients admitted with heart failure. <i>Journal of Internal Medicine</i> , 2008 , 264, 361-9	10.8	84
336	Current controversies and future perspectives in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 507-13	10.2	83
335	Measuring bronchodilation in COPD clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 379-84	9.4	83
334	Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 454-62	35.1	83
333	The prognostic importance of lung function in patients admitted with heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 685-91	12.3	80
332	The many "small COPDs": COPD should be an orphan disease. <i>Chest</i> , 2008 , 134, 623-627	5.3	78
331	Biomarkers to guide antibiotic therapy for COPD exacerbations. <i>The Cochrane Library</i> , 2018 ,	5.2	78
330	Aortic augmentation index: reference values in a large unselected population by means of the SphygmoCor device. <i>American Journal of Hypertension</i> , 2010 , 23, 180-5	2.3	77
329	Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 543-50	35.1	76
328	Sex differences in emphysema and airway disease in smokers. <i>Chest</i> , 2009 , 136, 1480-1488	5.3	76
327	Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. <i>European Respiratory Journal</i> , 2008 , 32, 17-24	13.6	76
326	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. <i>Respiratory Medicine</i> , 2016 , 114, 27-37	4.6	76
325	Resting heart rate is a predictor of mortality in COPD. <i>European Respiratory Journal</i> , 2013 , 42, 341-9	13.6	74
324	Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2005 , 25, 269-74	13.6	74
323	COPD: definition and phenotypes. <i>Clinics in Chest Medicine</i> , 2014 , 35, 1-6	5.3	73
322	Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. <i>European Respiratory Journal</i> , 1995 , 8, 1694-8	13.6	72
321	Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. <i>Respiratory Research</i> , 2011 , 12, 3	7.3	71

320	Changes in alcohol intake and mortality: a longitudinal population-based study. <i>Epidemiology</i> , 2004 , 15, 222-8	3.1	71
319	FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. <i>European Respiratory Journal</i> , 2013 , 42, 1391-401	13.6	70
318	Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. <i>Respiratory Medicine</i> , 2009 , 103, 136-43	4.6	70
317	Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. <i>Respiratory Medicine</i> , 2014 , 108, 729-36	4.6	69
316	Predictors of smoking reduction and cessation in a cohort of danish moderate and heavy smokers. <i>Preventive Medicine</i> , 2001 , 33, 46-52	4.3	68
315	Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. <i>Respiratory Medicine</i> , 2004 , 98, 1045-50	4.6	67
314	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , 2013 , 41, 1017-22	13.6	65
313	A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. <i>European Respiratory Journal</i> , 2009 , 33, 1039-44	13.6	65
312	Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. <i>Chest</i> , 2010 , 138, 1125-32	5.3	64
311	Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. <i>Journal of Epidemiology and Community Health</i> , 2003 , 57, 412-6	5.1	64
310	Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 460-4	10.2	64
309	Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly?. <i>American Journal of Hypertension</i> , 1997 , 10, 634-9	2.3	63
308	Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 426-434	35.1	62
307	Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 699-709	35.1	62
306	Predictors of objective cough frequency in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 943-9	10.2	62
305	Social position and mortality from respiratory diseases in males and females. <i>European Respiratory Journal</i> , 2003 , 21, 821-6	13.6	62
304	Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. <i>Thorax</i> , 2015 , 70, 33-40	7.3	61
303	Association of Cardiovascular Disease With Respiratory Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2166-2177	15.1	60

302	Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , 2017 , 26,	9.8	59
301	Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. <i>Respiratory Medicine</i> , 2009 , 103, 1572-9	4.6	59
300	The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 367-77	2	57
299	Smoking cessation intervention in a large randomised population-based study. The Inter99 study. <i>Preventive Medicine</i> , 2005 , 40, 285-92	4.3	57
298	Convergence of the epidemiology and pathology of COPD. <i>Thorax</i> , 2006 , 61, 86-8	7.3	57
297	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2015 , 109, 1138-46	4.6	56
296	Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017 , 390, 2247-2255	4.0	56
295	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 23-34	2.7	56
294	Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. <i>Clinical Respiratory Journal</i> , 2011 , 5, 44-9	1.7	55
293	C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. <i>Thorax</i> , 2011 , 66, 197-204	7.3	55
292	Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions. <i>PLoS ONE</i> , 2013 , 8, e82243	3.7	55
291	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. <i>Respiratory Research</i> , 2011 , 12, 71	7.3	54
290	Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. <i>European Respiratory Journal</i> , 2010 , 35, 532-9	13.6	54
289	Increased T-regulatory cells within lymphocyte follicles in moderate COPD. <i>European Respiratory Journal</i> , 2009 , 34, 89-94	13.6	53
288	COPD stage and risk of hospitalization for infectious disease. <i>Chest</i> , 2008 , 134, 46-53	5.3	51
287	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015 , 24, 159-72	9.8	50
286	Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. <i>Respirology</i> , 2015 , 20, 101-7	3.6	50
285	Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. <i>Respiratory Care</i> , 2011 , 56, 477-87	2.1	50

284	Biomarkers in chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2009 , 6, 543-5		49
283	Natural histories of chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2008 , 5, 878-83		49
282	It is possible to help smokers in early motivational stages to quit. The Inter99 study. <i>Preventive Medicine</i> , 2005 , 40, 278-84	4.3	49
281	A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 627-33		49
280	Factors associated with change in exacerbation frequency in COPD. <i>Respiratory Research</i> , 2013 , 14, 79	7.3	47
279	Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. <i>European Respiratory Journal</i> , 2016 , 47, 1365-73	13.6	46
278	Prevalence of COPD in Copenhagen. <i>Respiratory Medicine</i> , 2011 , 105, 410-7	4.6	45
277	Genetic influences on Chronic Obstructive Pulmonary Disease - a twin study. <i>Respiratory Medicine</i> , 2010 , 104, 1890-5	4.6	45
276	Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation. <i>Human Molecular Genetics</i> , 2008 , 17, 1890-903	5.6	45
275	Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005 , 60, 301-4	7.3	45
274	Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 163, 690-3	10.2	45
273	Should we continue using questionnaires on breathlessness in epidemiologic surveys?. <i>The American Review of Respiratory Disease</i> , 1988 , 137, 1114-8		45
272	High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. <i>Respiratory Research</i> , 2016 , 17, 125	7.3	44
271	COPD phenotype description using principal components analysis. <i>Respiratory Research</i> , 2009 , 10, 41	7.3	44
270	Beta-blockers in COPD: time for reappraisal. <i>European Respiratory Journal</i> , 2016 , 48, 880-8	13.6	44
269	Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. <i>Thorax</i> , 2020 , 75, 520-527	7.3	43
268	Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. <i>Journal of General Internal Medicine</i> , 2015 , 30, 51-9	4	42
267	Cardiovascular morbidity in COPD: A study of the general population. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010 , 7, 5-10	2	42

266	Changes in smoking habits and risk of asthma: a longitudinal population based study. <i>European Respiratory Journal</i> , 2001 , 18, 549-54	13.6	42
265	Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. <i>BMC Infectious Diseases</i> , 2016 , 16, 713	4	42
264	One-year change in health status and subsequent outcomes in COPD. <i>Thorax</i> , 2015 , 70, 420-5	7.3	40
263	High aortic augmentation index predicts mortality and cardiovascular events in men from a general population, but not in women. <i>European Journal of Preventive Cardiology</i> , 2013 , 20, 1005-12	3.9	40
262	Use of different exhaled nitric oxide multiple flow rate models in COPD. <i>European Respiratory Journal</i> , 2007 , 29, 651-9	13.6	40
261	Increase in prevalence and severity of asthma in young adults in Copenhagen. <i>Thorax</i> , 2000 , 55, 833-6	7.3	40
260	Does cytomegalovirus predict a poor prognosis in <i>Pneumocystis carinii</i> pneumonia treated with corticosteroids? A note for caution. <i>Chest</i> , 1995 , 108, 411-4	5.3	40
259	Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. <i>Human Genetics</i> , 2013 , 132, 79-90	6.3	39
258	Candidate genes for COPD in two large data sets. <i>European Respiratory Journal</i> , 2011 , 37, 255-63	13.6	39
257	Molecular Diagnosis of Intermediate and Severe α -Antitrypsin Deficiency: MZ Individuals with Chronic Obstructive Pulmonary Disease May Have Lower Lung Function Than MM Individuals. <i>Clinical Chemistry</i> , 2001 , 47, 56-62	5.5	39
256	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	38
255	Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. <i>Chest</i> , 2016 , 149, 916-26	5.3	38
254	Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. <i>Respiratory Research</i> , 2014 , 15, 103	7.3	38
253	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 881-888	10.2	38
252	Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. <i>Respiratory Medicine</i> , 2010 , 104, 1297-303	4.6	38
251	Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011 , 8, 121-35	2	38
250	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017 , 57, 35-46	5.7	37
249	Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 48-57	10.2	37

248	The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. <i>Journal of Human Hypertension</i> , 2012 , 26, 476-84	2.6	37
247	Chronic bronchitis in an elderly population. <i>Age and Ageing</i> , 2003 , 32, 636-42	3	37
246	Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 671-680	10.2	37
245	Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , 2018 , 73, 431-438	7.3	36
244	The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 160	3.5	36
243	Alveolar damage in AIDS-related <i>Pneumocystis carinii</i> pneumonia. <i>Chest</i> , 1997 , 111, 1193-9	5.3	36
242	Inhaled corticosteroid containing combinations and mortality in COPD. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	36
241	Prevalence of night-time dyspnoea in COPD and its implications for prognosis. <i>European Respiratory Journal</i> , 2014 , 43, 1590-8	13.6	35
240	Family based association analysis of the IL2 and IL15 genes in allergic disorders. <i>European Journal of Human Genetics</i> , 2006 , 14, 227-35	5.3	35
239	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , 2017 , 103, 1536-1542	5.1	34
238	Vitamin D, vitamin D binding protein, lung function and structure in COPD. <i>Respiratory Medicine</i> , 2013 , 107, 1578-88	4.6	34
237	The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2015 , 16, 101	7.3	34
236	Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes?. <i>Annals of Nutrition and Metabolism</i> , 2013 , 63, 239-47	4.5	34
235	The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. <i>International Journal of COPD</i> , 2009 , 4, 149-56	3	34
234	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 47-55	10.2	34
233	The revised GOLD 2017 COPD categorization in relation to comorbidities. <i>Respiratory Medicine</i> , 2018 , 134, 79-85	4.6	34
232	Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. <i>Respiratory Research</i> , 2014 , 15, 147	7.3	33
231	Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys. <i>Respiratory Medicine</i> , 2004 , 98, 78-83	4.6	33

230	Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 43	3.5	32
229	Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2014 , 108, 1336-44	4.6	32
228	Improved survival prediction from lung function data in a large population sample. <i>Respiratory Medicine</i> , 2009 , 103, 442-8	4.6	32
227	Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015 , 109, 1147-54	4.6	31
226	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1126-1137	15.1	31
225	Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. <i>European Journal of Human Genetics</i> , 2008 , 16, 1083-90	5.3	31
224	Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 1096.e1-1096.e17	5.9	30
223	Socioeconomic status and prognosis of COPD in Denmark. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014 , 11, 431-7	2	30
222	Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. <i>Thorax</i> , 2009 , 64, 950-5	7.3	30
221	Acceptance of the smoking cessation intervention in a large population-based study: the Inter99 study. <i>Scandinavian Journal of Public Health</i> , 2005 , 33, 138-45	3	30
220	Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. <i>Clinical Chemistry</i> , 2017 , 63, 823-832	5.5	29
219	Microfibrillar-associated protein 4 modulates airway smooth muscle cell phenotype in experimental asthma. <i>Thorax</i> , 2015 , 70, 862-72	7.3	29
218	A comparison of COPD patients with and without ACOS in the ECLIPSE study. <i>European Respiratory Journal</i> , 2016 , 47, 1559-62	13.6	29
217	Characteristics of undertreatment in COPD in the general population. <i>Chest</i> , 2013 , 144, 1811-1818	5.3	29
216	Overweight and obesity may lead to under-diagnosis of airflow limitation: findings from the Copenhagen City Heart Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 5-13	2	28
215	Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 100	3	28
214	Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010 , 7, 331-6	2	28
213	Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 605-13 ^{10.2}	10.2	28

212	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 128-149	0.7	27
211	A systematic review of breath analysis and detection of volatile organic compounds in COPD. <i>Journal of Breath Research</i> , 2016 , 10, 034002	3.1	27
210	Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 980-989	35.1	27
209	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 17-22	10.2	27
208	A comparison of mortality rates in three prospective studies from Copenhagen with mortality rates in the central part of the city, and the entire country. Copenhagen Center for Prospective Population Studies. <i>European Journal of Epidemiology</i> , 1998 , 14, 579-85	12.1	27
207	Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	26
206	Smoking reduction and biomarkers in two longitudinal studies. <i>Addiction</i> , 2006 , 101, 1516-22	4.6	26
205	COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. <i>European Respiratory Review</i> , 2020 , 29,	9.8	25
204	Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility. <i>BMC Medical Informatics and Decision Making</i> , 2015 , 15, 8	3.6	24
203	Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015 , 308, L1114-24	5.8	24
202	Validation of the i-BODE index as a predictor of hospitalization and mortality in patients with COPD participating in pulmonary rehabilitation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014 , 11, 381-7	2	24
201	Long-term survival for COPD patients receiving noninvasive ventilation for acute respiratory failure. <i>International Journal of COPD</i> , 2013 , 8, 215-9	3	24
200	Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. <i>European Journal of Radiology</i> , 2014 , 83, 2093-101	4.7	23
199	Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , 2013 , 107, 1722-30	4.6	23
198	Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. <i>International Journal of COPD</i> , 2017 , 12, 2917-2928	3	23
197	Methods for therapeutic trials in COPD: lessons from the TORCH trial. <i>European Respiratory Journal</i> , 2009 , 34, 1018-23	13.6	23
196	Association of PTGDR gene polymorphisms with asthma in two Caucasian populations. <i>Genes and Immunity</i> , 2007 , 8, 398-403	4.4	23
195	Smoking reduction intervention in a large population-based study. The Inter99 study. <i>Preventive Medicine</i> , 2005 , 40, 112-8	4.3	23

194	Medically treated exacerbations in COPD by GOLD 1-4: A valid, robust, and seemingly low-biased definition. <i>Respiratory Medicine</i> , 2015 , 109, 1562-8	4.6	22
193	Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. <i>Thorax</i> , 2011 , 66, 903-9	7.3	22
192	Natural history of COPD: Focusing on change in FEV1. <i>Respirology</i> , 2016 , 21, 34-43	3.6	22
191	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , 2017 , 131, 27-34	4.6	21
190	A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. <i>European Respiratory Journal</i> , 2013 , 41, 12-7	13.6	21
189	Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. <i>Respiratory Medicine</i> , 2011 , 105, 1338-44	4.6	21
188	Prognostic value of interleukin-8 in AIDS-associated <i>Pneumocystis carinii</i> pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995 , 151, 1058-62	10.2	21
187	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016 , 119, 87-95	4.6	21
186	Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 210-218	10.2	20
185	Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damage. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014 , 306, L887-95	5.8	20
184	A functional CD86 polymorphism associated with asthma and related allergic disorders. <i>Journal of Medical Genetics</i> , 2007 , 44, 509-15	5.8	20
183	Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. <i>Chest</i> , 2015 , 148, 16-23	5.3	19
182	The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD. <i>Lung</i> , 2016 , 194, 889-895	2.9	19
181	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. <i>Human Molecular Genetics</i> , 2018 , 27, 3801-3812	5.6	19
180	Significant linkage to chromosome 12q24.32-q24.33 and identification of SFRS8 as a possible asthma susceptibility gene. <i>Thorax</i> , 2006 , 61, 874-9	7.3	19
179	Highly significant linkage to chromosome 3q13.31 for rhinitis and related allergic diseases. <i>Journal of Medical Genetics</i> , 2006 , 43, e10	5.8	19
178	Susceptibility to chronic mucus hypersecretion, a genome wide association study. <i>PLoS ONE</i> , 2014 , 9, e91621	3.7	19
177	Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. <i>Current Drug Targets</i> , 2013 , 14, 235-45	3	19

176	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2014 , 108, 1647-54	4.6	18
175	Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015 , 10, 293-307	3	18
174	Management and survival of patients admitted with an exacerbation of COPD: comparison of two Danish patient cohorts. <i>Clinical Respiratory Journal</i> , 2010 , 4, 208-14	1.7	18
173	Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 252-6		18
172	Long-term exposure to cement dust and later hospitalization due to respiratory disease. <i>International Archives of Occupational and Environmental Health</i> , 1990 , 62, 217-20	3.2	18
171	Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. <i>Respiratory Research</i> , 2019 , 20, 63	7.3	17
170	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	17
169	Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	17
168	Cigarette smoking and response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	17
167	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018 , 39, 3128-3134	9.5	17
166	Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014 , 51, 678-87	5.7	17
165	Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. <i>Thorax</i> , 2005 , 60, 343-9	7.3	17
164	The global impact of Aspergillus infection on COPD. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 241	3.5	17
163	Iron Deficiency in COPD Associates with Increased Pulmonary Artery Pressure Estimated by Echocardiography. <i>Heart Lung and Circulation</i> , 2017 , 26, 101-104	1.8	16
162	Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	16
161	Left ventricular volume and wall stress are linked to lung function impairment in COPD. <i>International Journal of Cardiology</i> , 2018 , 261, 172-178	3.2	16
160	Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. <i>Clinical Epidemiology</i> , 2017 , 9, 231-243	5.9	16
159	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020 , 158, 952-964	5.3	15

158	Effectiveness efficacy trials in COPD: how study design influences outcomes and applicability. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	15
157	The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 955-959.e6	5.9	15
156	Prevalence of airflow obstruction in patients with stable systolic heart failure. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 6	3.5	15
155	Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease. <i>Scientific World Journal, The</i> , 2014 , 2014, 140736	2.2	15
154	Enzyme-linked immunosorbent assay characterization of basal variation and heritability of systemic microfibrillar-associated protein 4. <i>PLoS ONE</i> , 2013 , 8, e82383	3.7	15
153	Importance of Early COPD in Young Adults for Development of Clinical COPD: Findings from the Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1245-1256	10.2	15
152	Fibrinogen and α -antitrypsin in COPD exacerbations. <i>Thorax</i> , 2015 , 70, 1014-21	7.3	14
151	Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. <i>BMJ Open Respiratory Research</i> , 2020 , 7,	5.6	14
150	β Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 608-614	4.7	14
149	Impact of diagnostic criteria on the prevalence of COPD. <i>Clinical Respiratory Journal</i> , 2013 , 7, 297-303	1.7	14
148	Is chronic obstructive pulmonary disease associated with increased arterial stiffness?. <i>Respiratory Medicine</i> , 2012 , 106, 397-405	4.6	14
147	Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials. <i>ERJ Open Research</i> , 2019 , 5,	3.5	13
146	COPD monocytes demonstrate impaired migratory ability. <i>Respiratory Research</i> , 2017 , 18, 90	7.3	13
145	Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , 2016 , 6, 114	8.9	13
144	Can patients with COPD self-manage?. <i>Lancet, The</i> , 2012 , 380, 624-5	4.0	13
143	CD8 chemokine receptors in chronic obstructive pulmonary disease. <i>Clinical and Experimental Immunology</i> , 2008 , 154, 56-63	6.2	13
142	Quantitative linkage genome scan for atopy in a large collection of Caucasian families. <i>Human Genetics</i> , 2007 , 121, 83-92	6.3	13
141	Factor V leiden homozygosity, dyspnea, and reduced pulmonary function. <i>Archives of Internal Medicine</i> , 2005 , 165, 2032-6		13

140	Are respiratory symptoms and chronic airflow limitation really associated with an increased risk of respiratory cancer?. <i>International Journal of Epidemiology</i> , 1991 , 20, 375-8	7.8	13
139	Prospective observational study in patients with obstructive lung disease: NOVELTY design. <i>ERJ Open Research</i> , 2019 , 5,	3.5	12
138	Prevention of COPD exacerbations: medications and other controversies. <i>ERJ Open Research</i> , 2015 , 1,	3.5	12
137	The severity of airways obstruction as a determinant of treatment response in COPD. <i>International Journal of COPD</i> , 2006 , 1, 209-18	3	12
136	Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis. <i>Hemodialysis International</i> , 2016 , 20, 68-77	1.7	12
135	Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis. <i>Frontiers in Immunology</i> , 2018 , 9, 3013	8.4	12
134	Substantial need for early diagnosis, rehabilitation and treatment of chronic obstructive pulmonary disease. <i>Danish Medical Journal</i> , 2012 , 59, A4396	3.8	12
133	Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort. <i>Scientific Reports</i> , 2019 , 9, 4064	4.9	11
132	FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. <i>International Journal of COPD</i> , 2020 , 15, 1135-1142	3	11
131	Biomarkers of collagen turnover are related to annual change in FEV in patients with chronic obstructive pulmonary disease within the ECLIPSE study. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 164	3.5	11
130	The prognostic significance of lung function in stable heart failure outpatients. <i>Clinical Cardiology</i> , 2017 , 40, 1145-1151	3.3	11
129	The EXACT-Pro: measuring exacerbations of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 287-8	10.2	11
128	Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study. <i>Journal of Sleep Research</i> , 2020 , 29, e12979	5.8	11
127	What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs. <i>International Journal of COPD</i> , 2018 , 13, 3485-3492	3	11
126	Small airway dysfunction in well-treated never-smoking HIV-infected individuals. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	10
125	Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population. <i>International Journal of COPD</i> , 2019 , 14, 853-861	3	10
124	The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. <i>Thorax</i> , 2015 , 70, 757-63	7.3	10
123	Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. <i>Respiratory Medicine</i> , 2019 , 155, 141-147	4.6	10

122	Association between vitamin D status and COPD phenotypes. <i>Lung</i> , 2014 , 192, 493-7	2.9	10
121	A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations. <i>ERJ Open Research</i> , 2019 , 5,	3.5	10
120	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 689-698	10.2	10
119	Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis. <i>European Clinical Respiratory Journal</i> , 2020 , 7, 1757274	2	9
118	A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 114	3.5	9
117	Susceptibility to exacerbation in COPD. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e29	35.1	9
116	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. <i>International Journal of COPD</i> , 2018 , 13, 1125-1134	3	8
115	Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. <i>Respiratory Medicine</i> , 2018 , 141, 198-206	4.6	8
114	Computed tomography quantification of emphysema in people living with HIV and uninfected controls. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	8
113	Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study. <i>Npj Primary Care Respiratory Medicine</i> , 2017 , 27, 25	3.2	8
112	Are pharmacists reducing COPD'S impact through smoking cessation and assessing inhaled steroid use?. <i>Respiratory Medicine</i> , 2012 , 106, 230-4	4.6	8
111	COPD: a prevalence estimation model. <i>Respirology</i> , 2005 , 10, 594-602	3.6	8
110	Comparison of five major airflow limitation criteria to identify high-risk individuals with COPD: a contemporary population-based cohort. <i>Thorax</i> , 2020 , 75, 944-954	7.3	8
109	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 29-39	4.7	8
108	Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk. <i>International Journal of COPD</i> , 2020 , 15, 543-552	3	7
107	Systemic inflammation and progression of COPD. <i>Thorax</i> , 2007 , 62, 469-70	7.3	7
106	Exhaled CO, a predictor of lung function?. <i>Respiratory Medicine</i> , 2007 , 101, 581-6	4.6	7
105	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. <i>ERJ Open Research</i> , 2020 , 6,	3.5	7

104	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	7
103	End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2019 , 160, 105814	4.6	7
102	Automated oxygen control with O2matic during admission with exacerbation of COPD. <i>International Journal of COPD</i> , 2018 , 13, 3997-4003	3	7
101	Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls. <i>Journal of Infectious Diseases</i> , 2020 , 221, 1973-1977	7	6
100	Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2020 , 10, e035640	3	6
99	Seretide withdrawal increases airway inflammation in moderate COPD patients. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1165-6	2.8	6
98	GOLD and the fixed ratio. <i>European Respiratory Journal</i> , 2011 , 38, 481-2; author reply 482-4	13.6	6
97	Evidence for an asthma risk locus on chromosome Xp: a replication linkage study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008 , 63, 1235-8	9.3	6
96	Chronic cough and phlegm in young adults: should we worry?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 2-3	10.2	6
95	The single-breath nitrogen test, mortality, and cancer. <i>The American Review of Respiratory Disease</i> , 1990 , 142, 1022-5		6
94	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	6
93	A new Cochrane review on electronic cigarettes for smoking cessation: should we change our practice?. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	6
92	Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 204-213	2.7	6
91	Real-World Data and Randomised Controlled Trials: The Salford Lung Study. <i>Advances in Therapy</i> , 2020 , 37, 977-997	4.1	6
90	Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. <i>Respiratory Research</i> , 2020 , 21, 2027-3	7.3	6
89	Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	6
88	Reply: correctly defining criteria for diagnosing chronic obstructive pulmonary disease matters. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 230-1	10.2	6
87	βAdrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study. <i>Thorax</i> , 2019 , 74, 934-940	7.3	5

86	Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 1307-1310	10.2	5
85	Chronic Mucus Hypersecretion and the Natural History of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 602-3	10.2	5
84	Absence of <i>Pneumocystis jirovecii</i> Colonization in Human Immunodeficiency Virus-Infected Individuals With and Without Airway Obstruction and With Undetectable Viral Load. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw044	1	5
83	Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension. <i>Liver International</i> , 2011 , 31, 1381-7	7.9	5
82	Has risk associated with smoking increased? Results from the Copenhagen Center for Prospective Population Studies. <i>International Journal of Epidemiology</i> , 1997 , 26, 1214-8	7.8	5
81	Predictive value of the single-breath nitrogen test for hospitalization due to respiratory disease. <i>Lung</i> , 1990 , 168, 93-101	2.9	5
80	ERS Statement: A core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations. <i>European Respiratory Journal</i> , 2021 ,	13.6	5
79	Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?. <i>Clinics in Chest Medicine</i> , 2020 , 41, 463-474	5.3	5
78	Automatic oxygen titration with O2matic [®] to patients admitted with COVID-19 and hypoxemic respiratory failure. <i>European Clinical Respiratory Journal</i> , 2020 , 7, 1833695	2	5
77	Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. <i>Life</i> , 2020 , 10,	3	5
76	Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 910-920	10.2	5
75	Supernormal lung function and risk of COPD: A contemporary population-based cohort study. <i>EClinicalMedicine</i> , 2021 , 37, 100974	11.3	5
74	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	5
73	Triple Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1082-1083	10.2	4
72	The emerging Chinese COPD epidemic. <i>Lancet, The</i> , 2018 , 391, 1642-1643	40	4
71	COPD drugs: the urgent need for innovation. <i>Lancet Respiratory Medicine, the</i> , 2014 , 2, 14-5	35.1	4
70	Incidental lung cancers and positive computed tomography images in people living with HIV. <i>Aids</i> , 2017 , 31, 1973-1977	3.5	4
69	Another piece of the inhaled corticosteroids-in-COPD puzzle. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 514-5	10.2	4

68	Scintigraphic demonstration of the thoracic duct following oral ingestion of 123I-heptadecanoic acid. <i>Gastrointestinal Radiology</i> , 1989 , 14, 212-4		4
67	Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. <i>Clinical Infectious Diseases</i> , 2020 , 71, 3214-3221	11.6	4
66	Telemediated Training in the Home as a Part of the Everyday Life and Practice With Very Severe Chronic Obstructive Pulmonary Disease. <i>Qualitative Health Research</i> , 2020 , 30, 2132-2145	3.9	4
65	Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease With Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 1963-1973	8.4	4
64	Personality Traits and Mental Symptoms are Associated with Impact of Chronic Obstructive Pulmonary Disease on Patients' Daily Life. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 773-778	2	4
63	Inhaled glucocorticoids in COPD: immortal time bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003 , 168, 127	10.2	4
62	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , 2019 , 5,	3.5	3
61	Long-Acting βAgonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1641-1644	10.2	3
60	Changes in GOLD: today and tomorrow. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 424-6	35.1	3
59	Lung function decline in COPD trials. <i>European Respiratory Journal</i> , 2009 , 33, 708-9; author reply 709-10	13.6	3
58	To use or not to use: clinical decision making in the face of uncertainty. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 284-5	10.2	3
57	Rapid detection of cytomegalovirus in bronchoalveolar lavage fluid and serum samples by polymerase chain reaction: correlation of virus isolation and clinical outcome for patients with human immunodeficiency virus infection. <i>Clinical Infectious Diseases</i> , 1997 , 24, 878-83	11.6	3
56	Statistical analysis of COPD exacerbations. <i>European Respiratory Journal</i> , 2008 , 32, 1421-2	13.6	3
55	COPD in the ECRHS. <i>Thorax</i> , 2004 , 59, 89-90	7.3	3
54	Small-airways dysfunction in never smoking asbestos exposed Danish plumbers. <i>International Archives of Occupational and Environmental Health</i> , 1990 , 62, 209-12	3.2	3
53	Psychometric Properties of the COPD-Specific Beliefs About Medicine Questionnaire in an Outpatient Population: A Rasch-Analysis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016 , 3, 748-757	2.7	3
52	Effectiveness of Fluticasone Furoate-Vilanterol in COPD. <i>New England Journal of Medicine</i> , 2016 , 375, 2607	59.2	3
51	Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. <i>Respiratory Medicine</i> , 2019 , 147, 58-65	4.6	3

50	Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1690-1698	7	3
49	Was the implementation strategy of the ProACT trial adequately proactive?. <i>Breathe</i> , 2019 , 15, 77-80	1.8	2
48	Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. <i>Respiratory Medicine</i> , 2020 , 173, 106185	4.6	2
47	Decade of the lung--a call for action to promote lung health globally. <i>Lancet Respiratory Medicine</i> , 2016 , 4, e3-e4	35.1	2
46	A Novel Study Design for the Comparison Between Once-Daily QVA149 and Twice-Daily Salmeterol/Fluticasone on the Reduction of COPD Exacerbations: The FLAME Study. <i>Chest</i> , 2014 , 145, 408A	5.3	2
45	Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 466-468	35.1	2
44	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021 , 7,	3.5	2
43	The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation. <i>International Journal of COPD</i> , 2018 , 13, 3885-3894	3	2
42	COPD 2016 , 751-766.e7		1
41	Paper acceptance time in respiratory research: room for improvement?. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	1
40	Regional differences in rate of FEV decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	1
39	Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. <i>ERJ Open Research</i> , 2020 , 6,	3.5	1
38	Outcomes consequent to "early" COPD for interventional studies. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	1
37	A rational approach to e-cigarettes: challenging ERS policy on tobacco harm reduction. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	1
36	NICE and GOLD response. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 442	35.1	1
35	S51 Circulating Desmosine Relates To Cardiovascular Comorbidity, Coronary Artery Calcification Score (cacs), Systemic Inflammation And Mortality In Patients With Copd. <i>Thorax</i> , 2014 , 69, A28-A29	7.3	1
34	'Highlights from this issue' in the November issue of Thorax. <i>Thorax</i> , 2013 , 68, 387-8	7.3	1
33	COPD, diagrams and traditions: time to move on?. <i>Thorax</i> , 2008 , 63, 755-6	7.3	1

32	Observational Studies of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Misconstrued Immortal Time Bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 464a-465	10.2	1
31	The Natural History of COPD115-123		1
30	Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population.. <i>Respiratory Medicine</i> , 2021 , 192, 106725 ^{4.6}	4.6	1
29	Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. <i>Respiratory Research</i> , 2021 , 22, 155	7.3	1
28	Natural experiments and large databases in respiratory and cardiovascular disease. <i>European Respiratory Review</i> , 2016 , 25, 130-4	9.8	1
27	Validation of lung density indices by cardiac CT for quantification of lung emphysema. <i>International Journal of COPD</i> , 2018 , 13, 3321-3330	3	1
26	Exhaled breath condensate in chronic obstructive pulmonary disease: methodological challenges and clinical application 2018 , 57,		1
25	Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	1
24	Stigma: an unmet public health priority in COPD. <i>Lancet Respiratory Medicine,the</i> , 2021 , 9, 955-956	35.1	1
23	Reorganisation of acute referral to an emergency department resulted in fewer admissions for chronic obstructive pulmonary disease but in higher rates of non-invasive ventilation. <i>Danish Medical Journal</i> , 2014 , 61, A4958	3.8	1
22	Another public health catastrophe.. <i>Lancet, The</i> , 2021 , 398, 2243	40	1
21	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).. <i>Trials</i> , 2022 , 23, 307	2.8	1
20	Should e-cigarettes be licensed as medicines?. <i>BMJ, The</i> , 2022 , 376, n2912	5.9	0
19	Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms.. <i>PLoS ONE</i> , 2022 , 17, e0262898 ^{3.7}	3.7	0
18	Re-assessing the importance of FEV1decline134-142		0
17	Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. <i>Frontiers in Immunology</i> , 2021 , 12, 668113	8.4	0
16	Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply. <i>Lancet, The</i> , 2018 , 392, 1113-1114	40	0
15	Management of chronic obstructive pulmonary disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021 , 82, 1-10	0.8	0

14	Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD.. <i>European Respiratory Journal</i> , 2022 ,	13.6	0
13	Exposure Interaction: A Lifelong Phenomenon with Relevance to Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 947-948	10.2	
12	The TRINITY study: Twitter discussion from a respirology journal club - Authors' reply. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e26	35.1	
11	GOLD and the fixed ratio. <i>International Journal of COPD</i> , 2012 , 7, 663; author reply 664	3	
10	Reply: Comorbidities and chronic obstructive pulmonary disease: is there a place for lung fibrosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1368	10.2	
9	Outpatient management of chronic obstructive pulmonary disease. <i>Clinical Medicine</i> , 2004 , 4, 220-4	1.9	
8	Clinical Assessment of COPD 2011 , 21-31		
7	Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. <i>Respiratory Research</i> , 2020 , 21, 263	7.3	
6	Increased serum SP-D in identification of high-risk smokers at high risk of COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021 , 320, L1005-L1010	5.8	
5	Transformations of practice in online exercise training for patients with COPD led by physiotherapists - a qualitative study. <i>Disability and Rehabilitation</i> , 2021 , 1-10	2.4	
4	The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea. <i>Sleep and Biological Rhythms</i> , 2021 , 19, 399-408	1.3	
3	Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021 , 223, 94-100	7	
2	Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease. <i>Respiratory Medicine</i> , 2021 , 186, 106529	4.6	
1	Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study.. <i>Respiratory Medicine</i> , 2022 , 197, 106852	4.6	